ExodusPoint Capital Management LP boosted its position in 2seventy bio, Inc. (NASDAQ:TSVT – Free Report) by 41.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,457,390 shares of the company’s stock after buying an additional 428,350 shares during the period. ExodusPoint Capital Management LP owned approximately 2.90% of 2seventy bio worth $14,749,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of TSVT. State Street Corp acquired a new position in 2seventy bio in the first quarter valued at $53,909,000. Wellington Management Group LLP acquired a new position in shares of 2seventy bio during the first quarter valued at about $42,854,000. BlackRock Inc. acquired a new position in shares of 2seventy bio during the first quarter valued at about $27,189,000. Balyasny Asset Management L.P. acquired a new position in shares of 2seventy bio during the first quarter valued at about $14,660,000. Finally, Vanguard Group Inc. acquired a new position in shares of 2seventy bio during the first quarter valued at about $23,549,000. Institutional investors and hedge funds own 98.49% of the company’s stock.
2seventy bio Price Performance
TSVT opened at $1.76 on Tuesday. 2seventy bio, Inc. has a fifty-two week low of $1.65 and a fifty-two week high of $16.17. The firm has a market capitalization of $89.10 million, a PE ratio of -0.45 and a beta of 1.49. The company’s 50-day moving average is $3.30 and its 200 day moving average is $7.07.
Wall Street Analysts Forecast Growth
2seventy bio Company Profile
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and chimeric antigen receptor-T cell product candidates for the treatment of multiple myeloma.
- Five stocks we like better than 2seventy bio
- ETF Screener: Uses and Step-by-Step Guide
- Zoom Video Communications: A tech phoenix ready to rise
- Transportation Stocks Investing
- The only two airline stocks worth buying: One is a Goldman pick
- How to Calculate Options Profits
- Ride the momentum: Apparel stocks soaring at 52-week highs
Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.